Previous studies have shown that CD4+T cell mitochondrial disorders can disrupt their metabolic pattern in patients with MS, which can lead to disrupted differentiation of CD4+T cell subsets, thereby triggering a Th17/Treg skew towards Th17 cells and enhancing the inflammatory response in vivo [142–145]. Here, CD4 is linked to myeloid sarcoma.